Robotic Radiotherapy Market – By Product, By Technology, By Application, By End Use – Global Forecast, 2025 – 2034

Robotic Radiotherapy Market Size

The global robotic radiotherapy market size was valued at USD 1.2 billion in 2024 and is projected to exhibit 11.6% CAGR from 2025-2034. The market includes radiation therapy products which utilize robotics to deliver therapy for cancer and other tumors with high precision. In complex cancer surgeries, robotic treatment improves accuracy, patient outcomes, and decreases treatment sessions (hypofractionation).
 

The increased global burden of cancer is fuelling the growth of the market. Based on estimates by the World Health Organization (WHO), more than 35 million new cases of cancer are estimated in 2050, a 77% increase compared to an estimated 20 million cases in 2022. Robotic radiotherapy delivers targeted tumor radiation while sparing surrounding normal tissue, especially useful in the treatment of complex and challenging-to-reach tumors. This burdensome increase in cancer highlights the urgent necessity for better radiotherapy solutions in healthcare systems globally.
 

Technological innovations in real-time imaging, artificial intelligence, and motion tracking have enhanced the precision of robotic radiotherapy systems. These technologies enable adaptive radiation delivery, which compensates for tumor motion due to breathing or patient motion.
 

Patients and healthcare professionals alike increasingly favor minimally invasive, outpatient procedures that reduce hospital stay and recovery time. Robotic radiotherapy systems enable the delivery of high radiation doses with no surgery or extended hospitalization, indicating a radical shift towards ambulatory care sites.
 

Government and private investment is also expanding oncology infrastructure, especially in emerging markets. The National Institutes of Health (NIH) states that in total around the world, an estimated 9.6 million people die of cancer yearly, with 70% of those fatalities occurring in low? and middle?income countries, highlighting the urgent need for increased cancer care infrastructure. Additionally, based on the Clinical Oncology Journal, over 50% of cancer patients in need of radiotherapy in low- and middle-income nations do not have access to treatment. Nations are setting and revising reimbursement policies to cover advanced radiotherapy technologies.
 

Robotic Radiotherapy Market Trends

• The application of AI and machine learning by robotic radiotherapy systems are enabling automatic treatment planning, improving dose prediction accuracy, and are enhancing image-guided radiotherapy.
• The new techniques have enabled real-time adjustment of treatment based on the tumor response, resulting in more personalized and efficient treatments. This advancement has revolutionized radiotherapy planning and delivery with increased accuracy and reduced planning time.
   
• Growing adoption of hypofractionation is enabling robotic radiotherapy systems to deliver higher doses of radiation over fewer fractions. Precision in beam delivery is also preventing damaging of normal tissues during hypofractionation-based treatments.
   
• This has led to reduction in treatment duration, boosted the throughput of the clinic, and has lowered healthcare expenditures, benefiting both patients and providers. Hypofractionation has specifically become critical in prostate, lung, and brain cancer treatments.
   
• Robotic radiotherapy is finding applications beyond brain and spinal tumors for the treatment of lung, liver, pancreas, and prostate tumors. Advanced motion tracking and adaptive planning capabilities are enabling safe delivery of treatment in complex anatomy or moving areas. The extension of application has illustrated enhanced clinical acceptance of robotic technology and have expanded treatment indication.
   

Trump Administration Tariffs

• The Trump-administration tariffs on medical equipment and electronics imported from China are predicted to raise the costs of production and procurement for robotic radiotherapy systems.
   
• Domestic and foreign manufacturers that rely on core components like imaging sensors, robot actuators, and semiconductor chips are expected to face a higher impact from the tariffs. This is likely to increase total manufacturing and import expenses of final systems, posing financial constraints to suppliers and reducing affordability among healthcare providers.
   
• Further, tariff uncertainty across costs is anticipated to prompt hospitals and ambulatory surgical centers to cancel or postpone investments in capital equipment such as robotic radiotherapy units.
   
• Healthcare providers are expected to put off purchasing until the situation improves, or some alternatives are available, which will likely cause shifts in buying patterns and possibly lead to an increase in market scope, including small and medium-sized healthcare facilities.
   
• Tariffs are likely to force medical device manufacturers to rethink their international supply chains. Vendors that import components or manufactured systems from tariff-affected countries, especially China, are expected to shift or diversify their supplier base.
   
• The transition is predicted to lead to logistical complexities, longer lead times, and may affect product availability. Such supply chain evolution is likely to bring operational sophistication and may slow the adoption of robotic radiotherapy technology across certain countries.
   

Robotic Radiotherapy Market Analysis

Based on product, the market is segmented into radiotherapy systems, 3D cameras, software, and other products. The radiotherapy systems segment dominated the market with the largest revenue share of 56.2% in 2024.
 

• Robotic radiotherapy devices provide sub-millimeter accuracy in irradiating tumors with minimal injury to surrounding healthy tissues. Such accuracy is necessary to treat complex anatomy locations such as the brain, spine, and prostate.
   
• Growing emphasis on the effectiveness of treatment and less side effect has augmented the demand for systems such as CyberKnife and robotically guided LINACs in cancer facilities around the world.
   
• The synergy between robotics, high-resolution imaging, and artificial intelligence has increased radiotherapy delivery capability. Newer robotic technologies integrate advanced treatment planning systems and advanced image processing.
   
• These capabilities enable clinicians to deliver customized therapy with greater accuracy and operational efficiency. The inclusion of these features continues to propel system adoption, especially among specialized cancer treatment centers.
   

Based on technology, the robotic radiotherapy market is segmented into linear accelerators, stereotactic radiation therapy systems, cyberknife, gamma knife, particle therapy, proton beam therapy, and heavy ion beam therapy. The linear accelerators segment dominated the market with the largest revenue of USD 512.2 million in 2024.
 

• Robotic linear accelerator systems offer capabilities for real-time imaging, beam modulation, and adaptive planning for accurate tumor targeting within complex anatomical sites. These systems monitor tumor motion during treatment, especially in respiratory-impacted organs such as lungs, and adapt radiation beams accordingly. This precision supports the use of high-dose, hypofractionated radiotherapy regimens in outpatient situations.
   
• The increasing number of cancers in hard-to-reach sites such as pancreatic, liver, and thoracic areas drives the use of robotic linear accelerator systems. The International Agency for Research on Cancer (IARC) reported 19.3 million new cancer cases in 2020 worldwide, with liver cancer accounting for 905,677 and pancreatic cancer accounting for 495,773 cases. As a result, the demand for linear accelerator technology based system is high, driving revenue growth in the segment.
   
• The synergism of robotic arm mobility with high-energy photon beams allows multiple-angle treatment delivery with sub-millimeter accuracy. According to the National Cancer Institute (NCI), 50% of all cancer patients are treated using radiation therapy, emphasizing the key importance of state-of-the-art radiation delivery systems-based on linear accelerators.
   
• By offering treatment for patients that are unable to have surgery or regular radiotherapy, this technology helps those patients with increasing numbers of patients having complex tumor locations.
   

Based on application, the robotic radiotherapy market is segmented into prostate cancer, breast cancer, lung cancer, head and neck cancer, colorectal cancer, and other applications. The prostate cancer segment dominated the market with the largest revenue of USD 413.9 million in 2024.
 

• Prostate cancer is the most frequently diagnosed cancer in men all over the world, with a tendency to increase in early-stage tumors owing to enhanced screening programs and PSA screening. For example, as reported by the World Cancer Research Fund, an estimated 1.5 million new prostate cancers were diagnosed worldwide in 2022.
   
• The rise in the number of early-stage cases, caused by improved screening programs and PSA testing, has generated an increased demand for accurate treatment methods.
   
• Robotic radiotherapy, with its minimal invasiveness and organ-sparing feature, presents patients with a possibility of an alternative to conventional surgery and traditional radiotherapy with lower side effects. This technology has dramatically enhanced outcomes for prostate cancer patients.
   
• Also, the use of hypofractionated radiotherapy in the management of prostate cancer continues to grow as it limits the sessions to be conducted while giving more radiation doses. Robotic systems have accurate sub-millimeter precision in the pelvic area, which makes safe delivery of these intense treatments possible.
   
• The increased clinical evidence in favor of the success of hypofractionation, together with the accuracy of robotic systems, has made robotic radiotherapy a cost-effective treatment regimen in prostate cancer treatment, favoring segments growth.
   

Based on end use, the robotic radiotherapy market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and research and academic institutions. The hospitals segment dominated the market with a share of 53.2% in 2024.
 

• Hospitals across the world are facing pressure to improve cancer care services in the context of increasing patient numbers and advanced treatment requirements. Robotic radiotherapy machines enable hospitals to offer high-precision, non-invasive cancer treatment for various types of tumors, driving their adoption.
   
• Additionally, the integration of these systems within hospital oncology services enhances clinical capability, supports multidisciplinary care, and helps institutions in becoming regional cancer care centers.
   
• The installation of robotic radiotherapy systems enables hospitals to boost their ability to treat cancer, which is further strengthened by the rising number of patients and doctors.
   
• Furthermore, robotic radiosurgery technology differentiates hospitals in competitive urban environments and private health networks. These systems enhance hospital prestige among referral physicians and payors, promoting patient growth and oncology service line development.
   

North America: The U.S. robotic radiotherapy market is projected to grow significantly from USD 508.3 million in 2024 to USD 1.5 billion by 2034.
 

• The rising number of cancer diagnoses in the United States, especially in the aging population, fuels the use of robotic radiotherapy systems. For example, as per the National Cancer Institute (NCI), about 1.9 million new cases of cancer were estimated in 2023, with an estimated 609,820 deaths from cancer.
   
• Furthermore, prostate, lung, colorectal, and breast cancers, often diagnosed in the elderly in the U.S., necessitate accurate treatments that avoid complications and preserve quality of life. The Centers for Disease Control and Prevention (CDC) states that these types of cancer are responsible for almost 50% of all new cancers each year.
   
• Robotic radiotherapy treatments are gaining increasing adoption in the country, providing non-invasive and hypofractionated treatments, further minimizing the number of patient visits and recovery time. This technology greatly enhances treatment outcomes for the increasing cancer patient population in the country, further aiding to the revenue growth.
   

Europe: The robotic radiotherapy market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The National Health Service (NHS) of the UK has ranked cancer care modernization high in its long-term plan by allocating resources for next-generation radiotherapy technologies. This involves installing robot systems to improve accuracy and patient outcomes.
   
• Centralized funding for the NHS diminishes the costs to public hospitals and facilitates increased access to robotic radiotherapy nationwide, especially to areas with underserved or high-demand populations.
   
• The aging factor of the UK population and increased incidence of cancer, especially prostate, lung, and colorectal cancer, has driven increased demand for precise, effective, and less invasive therapeutic procedures. In the UK alone, there are more than 385,000 new cancer diagnoses annually, as per the Cancer Research UK.
   
• Robotic radiotherapy devices provide accurate treatments that minimize healthy tissue damage and minimize side effects, making them particularly well-suited for frail or older patients who are unable to tolerate long treatment regimens. Hence, the above-mentioned factors are propelling market growth in the UK.
   

Asia Pacific: Japan robotic radiotherapy market is anticipated to witness lucrative growth between 2025 – 2034.
 

• Japan boasts the highest rate of elderly individuals in the world, with an enormous percentage of citizens aged 65 years and above. For instance, according to the World Economic Forum, the Japanese population comprises around 10% aged 80 years and above, and one-third aged 65 years and above. Such population is subject to high risk of cancer and usually are unable to receive invasive surgical interventions.
   
• Robotic radiotherapy as a non-surgical, highly accurate treatment modality is being preferred among elderly patients in Japan on an outpatient basis. The technique benefits older patients by reducing complications and recovery time without affecting their quality of life while undergoing cancer therapy.
   
• Further, Japan's universal healthcare system is operated by the country's Ministry of Health, Labour and Welfare (MHLW), making it easier to adopt advanced medical technology. The system offers reimbursement to robotic radiotherapy systems, such as CyberKnife, for certain medical conditions, making them more financially viable for medical facilities.
   
• In addition, both regulatory authorization and financial support encourage public hospitals and cancer centers to adopt robotic radiotherapy systems in line with national precision medicine programs, further aiding to the market growth.
   

Middle East and Africa: The Saudi Arabia robotic radiotherapy market is expected to experience significant and promising growth from 2025 to 2034.
 

• Cancer is among the leading causes of mortality in Saudi Arabia and is on the rise specifically in case of breast cancer, colorectal cancer, prostate cancer, and lung cancer. For instance, according to the Global Cancer Observatory, there were 28,133 new cases of cancer that occurred in Saudi Arabia in the year 2022.
   
• Owing to increasing awareness towards non-surgical options, that offers accurate treatment appropriate for such cancers in Saudi Arabia, there is an increasing focus on the population's early cancer detection and health awareness. This has spurred the demand for accurate treatment options such as robotic radiotherapy that offers minimal side effects and healthier tissue sparing.
   
• Further, Saudi Vision 2030 program targets the development and enhancement of healthcare facilities, especially oncology centers. The advanced radiotherapy equipment is being bought by the government to curb medical tourism and boost local cancer treatment capacity.
   
• These investments are made through public-private partnerships, the Ministry of Health, and institutions like the National Unified Procurement Company (NUPCO), which facilitate the incorporation of radiotherapy systems. The aforementioned factors thus supports the market growth in Saudi Arabia.
   

Robotic Radiotherapy Market Share

The market has a dynamic mix of international and domestic players providing innovative solutions to meet the growing demand for advanced systems for the growing patient population. Companies such as Siemens Healthineers, Elekta, Accuracy, ViewRay, and Ion Beam Applications are some of the dominant competitors in the market accounting for a combined market share of approximately 70%.
 

Competition in this area arises from continuous technological developments and the ability to offer customized solutions for various robotic radiotherapy applications. In developing nations, due to the priority given to cost, multinational companies are squeezed to offer robotic radiotherapy that are both affordable and of quality. Domestic manufacturers take advantage of this demand by providing cost effective alternatives, which make multinationals alter their price strategy while maintaining the safety, ruggedness, and regulatory acceptability of the products.
 

Robotic Radiotherapy Market Companies

Some of the eminent market participants operating in the robotic radiotherapy industry include:

• Accuray
• Brainlab
• Elekta
• GE Healthcare
• Hitachi
• Ion Beam Applications
• Mevion
• Mitsubishi Electric
• RefleXion
• Shinva
• Siemens Healthineers
• United Imaging
• Varian
• ViewRay
• ZAP
   
• Siemens Healthneers : Siemens Healthneers through its subsidiary, Varian offers Ethos and TrueBeam platforms, which couple adaptive radiotherapy with artificial intelligence to deliver patient-specific treatment. Its Ethos platform brings automation, AI, and precision to change treatment plans during the treatment session, maximizing results in prostate, lung, and head and neck cancers.
   
• Elekta : The Unity MR-LINAC system of Elekta combines real-time imaging via MRI with radiation delivery, providing better soft-tissue targeting for prostate, liver, and pancreatic cancers. The Gamma Knife system of the company continues to be the leading solution for non-invasive radiosurgery of brain tumors, underpinned by three decades of clinical data.
   
• Accuray: Accuray's CyberKnife system offers robotic stereotactic radiosurgery (SRS/SBRT) with sub-millimeter accuracy for tumors of the lung, prostate, and spine without invasive fixation. The Radixact tomotherapy system offers image-guided IMRT by helical delivery for complex treatments. The CyberKnife's robotic arm allows non-isocentric treatment with reduced side effects and the ability to provide outpatient treatment.
   

Robotic Radiotherapy Industry News:

• In January 2025, Accuray announced that the company's Radixact SynC System and CyberKnife S7 System had been approved by the Chinese National Medical Products Administration (NMPA). The approval strengthened Accuray's market access in China and expanded opportunities for revenue growth.
   
• In June 2024, Accuray announced a partnership with Apollo Cancer Centres (ACC) to launch the India Sub-Continent's first robotic and stereotactic therapy education centre, the Robotic & Stereotactic Radiosurgery Program. This collaboration enhanced Accuray’s regional presence and supported clinical adoption of its technologies through specialized training and education.
   
• In June 2021, Accuray announced the launch of RayStation treatment planning support for the company's CyberKnife M6 and S7 Robotic Radiotherapy Systems. RayStation enabled clinicians to develop treatment plans for both CyberKnife systems and conventional radiation therapy devices within a unified treatment planning system, streamlining integration within radiation oncology departments. The launch enhanced system interoperability and increased the appeal of Accuray’s technologies to a broader range of clinical settings.
   
• In July 2023, GE HealthCare, a leading global medical technology, diagnostics, and digital solutions innovator, extended its collaboration with Elekta, a leader in radiation therapy, in the Indian market to expand access to precision radiation therapy solutions. The partnership strengthened GE HealthCare’s position in oncology and broadened its reach in one of the fastest-growing healthcare markets.
   

The robotic radiotherapy market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

By Product

• Radiotherapy systems
• 3D cameras
• Software
• Other products

By Technology

• Linear accelerators
• Stereotactic radiation therapy systems
• Cyberknife
• Gamma knife
• Particle therapy
• Proton beam therapy
• Heavy ion beam therapy

By Application

• Prostate cancer
• Breast cancer
• Lung cancer
• Head and neck cancer
• Colorectal cancer
• Other applications

By End Use

• Hospitals
• Cancer treatment centers
• Academic and research institutions
• Specialty clinics

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific 
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE